<DOC>
	<DOCNO>NCT03070262</DOCNO>
	<brief_summary>Caffeic acid target inhibit GASC1 expression GASC1 confirm new oncogene several cancer include esophageal cancer . This study aim investigate efficiency safety coffeic acid chinese advanced esophageal squamous cell cancer ( ESCC ) .</brief_summary>
	<brief_title>The Efficacy Safety Caffeic Acid Esophageal Cancer</brief_title>
	<detailed_description>Background : More half global esophageal cancer case come China.80 percentage patient diagnose advanced disease suffer poor outcome.With development target therapy among cancer , overall survival life quality patient continuous improve recently.However , little report focus esophageal cancer target therapy . Caffeic acid ordinary drug use thrombocytopenia patient recieved chemotherapy . Newly study show caffeic acid target inhibit GASC1 expression , GASC1 confirm new oncogene esophageal cancer . Aim : investigate efficiency safety caffeic acid chinese advanced esophageal squamous cell cancer . Methods : 300 advance ESCC patient randomize two arm : CA group ( recieving coffeic acid treatment ) placebo group.In CA group , patient recieve coffeic acid treatment : 300mg , tid , po ; placebo group , shape placebo tablet deliveried patient . 1 year follow-up group patients.Patients arm receive way anti cancer therapy time . Primary endpoint : 3 month PFS ; Second endpoint : 1 year OS</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Caffeic acid</mesh_term>
	<criteria>Chinese esophageal squamous cell cancer stage IV disease recurrence chemotherapy , radiotherapy , palliative care go PS : â‰¥ 3 severe hepatic renal dysfunction hypercoagulability thrombocytosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>esophageal cancer</keyword>
	<keyword>caffeic acid</keyword>
</DOC>